Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.05−0.06 (-0.06%)
Close on Nov 18, 2026Market cap $14.94BP/E 73.1Yield –
Kiniksa Pharmaceuticals International revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Kiniksa Pharmaceuticals International's revenue for the twelve months ending Sep 30, 2026 was $945.96M, up 58.2% year over year. For fiscal 2025 it was $677.56M, up 60.1% from the year before. The highest annual figure on record is $677.56M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $677.56M | +60.1% |
| FY2024 | Dec 31, 2024 | $423.24M | +56.6% |
| FY2023 | Dec 31, 2023 | $270.26M | +22.7% |
| FY2022 | Dec 31, 2022 | $220.18M | +471.2% |
| FY2021 | Dec 31, 2021 | $38.54M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $285.97M | +58.1% |
| Q2 FY2026 | Jun 30, 2026 | $243.60M | +55.4% |
| Q1 FY2026 | Mar 31, 2026 | $214.27M | +55.5% |
| Q4 FY2025 | Dec 31, 2025 | $202.13M | +65.0% |
| Q3 FY2025 | Sep 30, 2025 | $180.86M | +61.2% |
| Q2 FY2025 | Jun 30, 2025 | $156.80M | +44.3% |
| Q1 FY2025 | Mar 31, 2025 | $137.79M | +72.5% |
| Q4 FY2024 | Dec 31, 2024 | $122.54M | +46.9% |
| Q3 FY2024 | Sep 30, 2024 | $112.21M | +67.4% |
| Q2 FY2024 | Jun 30, 2024 | $108.63M | +52.0% |
| Q1 FY2024 | Mar 31, 2024 | $79.86M | +65.2% |
| Q4 FY2023 | Dec 31, 2023 | $83.40M | +34.8% |
| Q3 FY2023 | Sep 30, 2023 | $67.05M | -32.4% |
| Q2 FY2023 | Jun 30, 2023 | $71.47M | +165.0% |
| Q1 FY2023 | Mar 31, 2023 | $48.35M | +50.2% |
| Q4 FY2022 | Dec 31, 2022 | $61.88M | +230.1% |
| Q3 FY2022 | Sep 30, 2022 | $99.14M | +719.6% |
| Q2 FY2022 | Jun 30, 2022 | $26.97M | +250.1% |
| Q1 FY2022 | Mar 31, 2022 | $32.19M | – |
| Q4 FY2021 | Dec 31, 2021 | $18.75M | – |
| Q3 FY2021 | Sep 30, 2021 | $12.10M | – |
| Q2 FY2021 | Jun 30, 2021 | $7.70M | – |
See a number that looks wrong?